HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01810783

Long-Term Brexpiprazole Treatment for Schizophrenia

About this titleRead the official source — NCT01810783
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Anaheim and 47 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2013
Recruitment status
Completed
Enrollment listed in the registry
210
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Estonia, Poland, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01810783
Official title
Show the full official title

Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Anaheim, United States · Cerritos, United States · Escondido, United States

38 more locations
  • Garden Grove, United States
  • Long Beach, United States
  • San Diego, United States
  • Washington D.C., United States
  • Kissimmee, United States
  • North Miami, United States
  • Lake Charles, United States
  • St Louis, United States
  • Cedarhurst, United States
  • Charleston, United States
  • Austin, United States
  • Dallas, United States
  • Pärnu, Estonia
  • Tallinn, Estonia
  • Choroszcz, Poland
  • Gdansk, Poland
  • Brasov, Romania
  • Bucharest, Romania
  • Iași, Romania
  • Piteşti, Romania
  • Arkhangelsk, Russia
  • Moscow, Russia
  • Rostov-on-Don, Russia
  • Saint Petersburg, Russia
  • Saratov, Russia
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Novi Kneževac, Serbia
  • Liptovský Mikuláš, Slovakia
  • Dnipropetrovsk, Ukraine
  • Geikivka, Ukraine
  • Hlevakha, Ukraine
  • Kherson, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Smila, Ukraine
  • Vinnytsia, Ukraine
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Did this study involve medication?

Yes. The study involved medication, including Brexpiprazole.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies